TIAA CREF Trust’s Novartis NVS Stock Holding History

TIAA CREF Trust’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1.74M	Sell	26,116 -6,708	-20%	-$447K	0.01%	239
2016 Q4	$2.14M	Sell	32,824 -10,754	-25%	-$698K	0.02%	197
2016 Q3	$3.08M	Sell	43,578 -6,219	-12%	-$453K	0.03%	151
2016 Q2	$3.68M	Sell	49,797 -15,554	-24%	-$1.07M	0.03%	141
2016 Q1	$4.24M	Sell	65,351 -24,406	-27%	-$1.66M	0.04%	133
2015 Q4	$6.92M	Sell	89,757 -7,121	-7%	-$566K	0.07%	114
2015 Q3	$7.98M	Sell	96,878 -4,111	-4%	-$366K	0.09%	103
2015 Q2	$8.9M	Sell	100,989 -19,245	-16%	-$1.77M	0.1%	100
2015 Q1	$10.6M	Sell	120,234 -6,527	-5%	-$579K	0.12%	86
2014 Q4	$10.5M	Sell	126,761 -6,286	-5%	-$521K	0.13%	85
2014 Q3	$11.2M	Sell	133,047 -37,007	-22%	-$2.99M	0.15%	80
2014 Q2	$13.8M	Sell	170,054 -18,038	-10%	-$1.42M	0.2%	65
2014 Q1	$14.3M	Sell	188,092 -10,083	-5%	-$735K	0.23%	62
2013 Q4	$14.3M	Buy	198,175 +2,595	+1%	+$180K	0.24%	63
2013 Q3	$13.4M	Buy	195,580 +7,459	+4%	+$493K	0.25%	51
2013 Q2	$11.9M	Buy	+188,121	New	+$12.2M	0.25%	52

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TIAA CREF Trust's NVS Position: Q1 2017 in Review

TIAA CREF Trust reduced its Novartis (NVS) stake by 20% in Q1 2017, selling an estimated $447K and leaving 26,116 shares worth $1.74M. The position accounts for 0.01% of the portfolio, ranked #239.

TIAA CREF Trust first reported a position in NVS in Q2 2013 and has held it in 16 quarters since. The position peaked at $14.3M in Q1 2014. 910 funds tracked by Wall St. Rank hold NVS as of Q1 2017.

TIAA CREF Trust held 26,116 shares of Novartis worth $1.74M as of Q1 2017.
TIAA CREF Trust sold 6,708 Novartis shares in Q1 2017, an estimated $447K.
Novartis made up 0.01% of TIAA CREF Trust's portfolio in Q1 2017, its #239 holding.
TIAA CREF Trust first reported a position in Novartis in Q2 2013 and has held it in 16 quarters since.
TIAA CREF Trust's Novartis position peaked at $14.3M in Q1 2014.
910 funds tracked by Wall St. Rank held Novartis as of Q1 2017.

Based on TIAA CREF Trust's 13F filing for Q1 2017, filed 3 May 2017.